In the last two decades major improvements have been reached in the early diagnosis of
colorectal cancer (CRC) and, besides chemotherapy, an ampler choice of therapeutic …

Acquired drug resistance in cancer results from Darwinian selection and evolution among
cancer cells, fuelled by their cell-heritable heterogeneity. As a consequence, targeted …

The dynamic cancer ecosystem, with its rich temporal and spatial diversity in environmental
conditions and heritable cell phenotypes, is remarkably robust to therapeutic perturbations …

Colorectal cancer is the third leading cause of cancer-related deaths throughout the world.
Surgery is effective against early stage tumors but advanced stage tumors lack an effective …

In a recent issue of Science, Russo et al. observe that colorectal cancer cells, when exposed
to the pressure of EGFR-and BRAF-targeted therapies, transiently alter their transcriptional …

Cancer is well-recognized as an evolutionary system, as first proposed by Cairns and
Nowell more than 60 years ago. In an evolutionary context, cancers growing in vivo typically …

Cancer is well-recognized as an evolutionary system, as first proposed by Cairns and
Nowell more than 60 years ago. In an evolutionary context, cancers growing in vivo typically …

Human society is engaged in an arms race against cancer, which pits one evolutionary
process—human cultural evolution as we develop novel cancer therapies—against another …

Our understanding of cancer is being transformed by exploring clonal diversity, drug
resistance, and causation within an evolutionary framework. The therapeutic resilience of …

Roots and routes of resistance | Science Translational Medicine news careers commentary
Journals Science Science brought to you byGoogle Indexer Log in journal-menu-img science …